Non-alcoholic fatty liver disease, cardiovascular system and kidney function in young adults
https://doi.org/10.21886/2712-8156-2023-4-3-15-21
Abstract
Over the past four decades, non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease, believed to affect more than 25% of adults worldwide. Unless specific testing is done to detect NAFLD, the disease is typically silent until advanced and potentially irreversible liver impairment occurs. NAFLD is associated with a higher risk of cardiovascular and kidney dysfunction, independent of obesity, type 2 diabetes, and other common risk factors. However, the mechanisms underlying this association remain largely unexplored. An increase in the incidence of NAFLD among young individuals is emphasized. However, despite the global prevalence of NAFLD throughout the world, prevalence among young remains unclear. The purpose of this review is to analyze the main cardiometabolic risk factors and NAFLD and association with cardiovascular disease and kidney dysfunction in young adults.
About the Authors
V. S. Chulkov
Yaroslav-the-Wise Novgorod State University
Russian Federation
Russian Federation
Chulkov Vasilii S. - Dr. Sci. (Med), Accossiated Professor.
Veliky Novgorod
E. D. Pankova
South-Ural State Medical University
Russian Federation
Russian Federation
Pankova Ekaterina D. - post-graduate student of the 2nd year of study of the Department of Faculty Therapy.
Chelyabinsk
N. D. Krasnopeeva
South-Ural State Medical University
Russian Federation
Russian Federation
Krasnopeeva Natalya D. - Senior Laboratory Assistant, Department of Faculty Therapy.
Chelyabinsk
Vl. S. Chulkov
South-Ural State Medical University
Russian Federation
Russian Federation
Chulkov Vladislas S. - Cand. Sci. (Med), Associate professor of the Department of Faculty Therapy.
Chelyabinsk
References
1. Еганян Р.А. Роль неалкогольной жировой болезни печени в развитии сердечно-сосудистых заболеваний. CardioСоматика. 2018;9(1):47–53.
2. Канорский С.Г. Неалкогольная жировая болезнь печени: современные подходы к диагностике и лечению. Южно-Российский журнал терапевтической практики. 2021;2(3):18-29. doi:10.21886/2712-8156-2021-2-3-18-29.
3. Лазебник Л.Б., Голованова Е.В., Туркина С.В., Райхельсон К.Л., Оковитый С.В., Драпкина О.М., и др. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021;1(1):4-52. doi: 10.31146/1682-8658-ecg-185-1-4-52
4. Чулков В.С., Гаврилова Е.С., Чулков В.С., Панкова Е.Д., Ленец Е.А., Ткаченко Е.А. Первичная профилактика сердечно-сосудистых заболеваний: акцент на коррекцию поведенческих факторов риска. Российский кардиологический журнал. 2021; 26(S3): 67-72. – doi: 10.15829/1560-4071-2021-4278
5. Чулков В.С., Сумеркина В.А., Абрамовских О.С., Чулков В.С. Частота неалкогольной жировой болезни печени у молодых пациентов с абдоминальным ожирением на фоне артериальной гипертензии. Экспериментальная и клиническая гастроэнтерология. 2014;11(111):42-45.
6. Ягода А.В., Гейвандова Т.В., Рогова С.Ш., Гейвандова Н.И. Полиморфизм гена рецептора лептина и лептинорезистентность при неалкогольной жировой болезни печени, ассоциированной с ожирением. Эффективная Фармакотерапия. 2019;15(18): 82-87. doi: 10.33978/2307-3586-2019-15-18-82-87
7. Ábel T. Nonalcoholic Fatty Liver Disease. Bentham Science Publishers. 2017:190.
8. Abeysekera K.W.M., Fernandes G.S., Hammerton G., Portal A.J., Gordon F.H., Heron J., et al. Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study. Lancet Gastroenterol Hepatol.2020;5(3):295–305. doi: 10.1016/S2468-1253(19)30419-4
9. An B.Q., Lu L.L., Yuan C., Xin Y.N., Xuan S.Y. Leptin Receptor Gene Polymorphisms and the Risk of Non-Alcoholic Fatty Liver Disease and Coronary Atherosclerosis in the Chinese Han Population. Hepat Mon. 2016 Apr 27;16(4):e35055. doi: 10.5812/hepatmon.35055
10. Boutari C., Mantzoros C.S.. Adiponectin and leptin in the diagnosis and therapy of NAFLD. Metabolism. 2020 Feb;103:154028. doi: 10.1016/j.metabol.2019.154028
11. Bugianesi E. Fatty liver disease: putting the spotlight on a silent menace for young adults. Lancet Gastroenterol Hepatol. 2020;5(3):236–238. doi: 10.1016/S2468-1253(19)30420-0
12. Byrne C.D., Patel J., Scorletti E., Targher G. Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults. BMJ. 2018;k2734. doi: 10.1136/bmj.k2734
13. Byrne C.D., Targher G. NAFLD as a driver of chronic kidney disease. J Hepatol. 2020;72(4):785–801. doi: 10.1016/j.jhep.2020.01.013
14. Costa-Urrutia P., Abud C., Franco-Trecu V., Colistro V., Rodríguez-Arellano M.E., Granados J., et al. Genetic susceptibility to pre diabetes mellitus and related association with obesity and physical fitness components in Mexican-Mestizos. Prim Care Diabetes.2018;12(5):416–424. doi: 10.1016/j.pcd.2018.07.005
15. El Hadi H., Di Vincenzo A., Vettor R., Rossato M. Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease. IJMS. 2019;20(9):2215. doi: 10.3390/ijms20092215
16. Francisco V., Sanz M.J., Real J.T., Marques P., Capuozzo M., Ait Eldjoudi D., et al. Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets? Biology (Basel). 2022;11(8):1237. doi: 10.3390/biology11081237
17. Fresneda S., Abbate M., Busquets-Cortés C., López-González A., Fuster-Parra P., Bennasar-Veny M., et al. Sex and age differences in the association of fatty liver index-defined non-alcoholic fatty liver disease with cardiometabolic risk factors: a cross-sectional study. Biol Sex Differ. 2022;13(1):64. doi: 10.1186/s13293-022-00475-7
18. Hill N.R., Fatoba S.T., Oke J.L., Hirst J.A., O’Callaghan C.A., Lasserson D.S., et al. Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. PLoS One. 2016;11(7):e0158765. doi: 10.1371/journal.pone.0158765
19. Jaruvongvanich V., Chenbhanich J., Sanguankeo A., Rattanawong P., Wijarnpreecha K., Upala S. Increased arterial stiffness in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017;29(9):28–35. doi: 10.1097/MEG.0000000000000909
20. Mantovani A., Csermely A., Petracca G., Beatrice G., Corey K.E., Simon T.G., et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(11):903-913. doi: 10.1016/S2468-1253(21)00308-3
21. Mendoza-Herrera K., Florio A.A., Moore M., Marrero A., Tamez M., Bhupathiraju S.N., et al. The Leptin System and Diet: A Mini Review of the Current Evidence. Front Endocrinol.2021;12:749050. doi: 10.3389/fendo.2021.749050
22. Lonardo A., Mantovani A., Targher G., Baffy G. Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Clinical and Research Implications. International Journal of Molecular Sciences. 2022; 23(21):13320. doi: 10.3390/ijms232113320
23. Okur G., Karacaer Z. The prevalence of non-alcoholic fatty liver disease in healthy young persons. North Clin Istanb. 2016;3(2):111–117. doi: 10.14744/nci.2016.28199
24. Paik J., Golabi P., Younoszai Z. , Mishra A., Trimble G. , M Younossi Z. Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease. Liver Int. 2019;39(2):342-352. doi: 10.1111/liv.13992.
25. Pennisi G., Di Marco V., Buscemi C., Mazzola G., Randazzo C., Spatola F., et al. Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population. J Gastroenterol Hepatol. 2021;36(9):2389–2396. doi: 10.1111/jgh.15523
26. Saremi L., Lotfipanah S., Mohammadi M., Hosseinzadeh H., Fathi-Kazerooni M., Johari B., et al. The Pro12Ala polymorphism in the PPAR-γ2 gene is not associated with an increased risk of NAFLD in Iranian patients with type 2 diabetes mellitus. Cell Mol Biol Lett. 2019;24:12. doi: 10.1186/s11658-019-0138-0
27. Saki S., Saki N., Poustchi H., Malekzadeh R. Assessment of Genetic Aspects of Non-alcoholic Fatty Liver and Premature Cardiovascular Events. Middle East J Dig Dis. 2020;12(2):65-88. doi: 10.34172/mejdd.2020.166
28. Su.Y., Liu Z., Yang L., Li Y., Jiang S., Yao H., Du G. PPARγ gene Pro12Ala variants reduce the risk of obese individuals to non-alcoholic fatty liver: A study in Uygur Chinese population residing in Northwestern China. Clin Res Hepatol Gastroenterol.2020 Nov;44(6):894-904. doi: 10.1016/j.clinre.2020.02.005
29. Shabalala S.C. The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling // Biomed Pharmacother. 2020;131:110785. doi: 10.1016/j.biopha.2020.110785
30. Shafi K.M., Misra A. From non-alcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD): A journey over 40 years. Diabetes Metab Syndr.2020;14(4):695-696. doi: 10.1016/j.dsx.2020.05.019
31. Sharma N., Sircar A., Anders H-J., Gaikwad A.B. Crosstalk between kidney and liver in non-alcoholic fatty liver disease: mechanisms and therapeutic approaches. Arch Physiol Biochem.2022 Aug;128(4):1024-1038. doi: 10.1080/13813455.2020.1745851
32. Stahl E.P., Dhindsa D.S., Lee S.K., Sandesara P.B., Chalasani N.P., Sperling L.S. Nonalcoholic Fatty Liver Disease and the Heart. Journal of the American College of Cardiology.2019;73(8):948–963. doi: 10.1016/j.jacc.2018.11.050
33. Targher G., Byrne C.D. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nat Rev Nephrol. 2017;13(5):297–310. doi: 10.1038/nrneph.2017.16
34. Villela-Nogueira C., Leite N., Cardoso C., Salles G. NAFLD and Increased Aortic Stiffness: Parallel or Common Physiopathological Mechanisms? IJMS. 2016;17(4):460. doi: 10.3390/ijms17040460
35. Yang M., Geng C.A., Liu X., Guan M. Lipid Disorders in NAFLD and Chronic Kidney Disease. Biomedicines. 2021;9(10):1405. doi: 10.3390/biomedicines9101405
36. Yu X., Chen C., Guo Y., Tong Y., Zhao Y., Wu L., et al. High NAFLD fibrosis score in non-alcoholic fatty liver disease as a predictor of carotid plaque development: a retrospective cohort study based on regular health check-up data in China. Annals of Medicine. 2021;53(1):1621–1631. doi: 10.1080/07853890.2021.1974081
37. Zhang X., Wu M., Liu Z., et al. Increasing prevalence of NAFLD/NASH among children, adolescents and young adults from 1990 to 2017: a population-based observational study. BMJ Open. 2021;11(5):e042843. doi: 10.1136/bmjopen-2020-042843
Supplementary files
Review
For citations:
Chulkov V.S., Pankova E.D., Krasnopeeva N.D., Chulkov V.S. Non-alcoholic fatty liver disease, cardiovascular system and kidney function in young adults. South Russian Journal of Therapeutic Practice. 2023;4(3):15-21. (In Russ.) https://doi.org/10.21886/2712-8156-2023-4-3-15-21
Views:
1053
Email this article 